Skip to main content
Erschienen in: Drugs & Aging 10/2005

01.10.2005 | Original Research Article

Prevention of Cardiovascular Events in Elderly People

verfasst von: Wafik Farah Andrawes, Caroline Bussy, Professor Joël Belmin

Erschienen in: Drugs & Aging | Ausgabe 10/2005

Einloggen, um Zugang zu erhalten

Abstract

Background and objective

Cardiovascular disease has been identified as the leading cause of morbidity and mortality in developed countries. Given the increase in life expectancy and the development of cardiovascular preventive measures, it has become increasingly important to detect and prevent cardiovascular diseases in the elderly. We reviewed the scientific literature concerning cardiovascular prevention to assess the importance of cardiovascular preventive measures in old (≥65 years of age) individuals.

Methods

We undertook a systematic search for references relating to prevention of cardiovascular disease in the elderly, mainly ischaemic stroke, coronary artery disease and heart failure, on the MEDLINE database 1962–2005. For cardiovascular prevention by drugs or surgery, emphasis was placed on randomised controlled trials, review articles and meta-analyses. For cardiovascular prevention by lifestyle modification, major cohort studies were also considered.

Results

Stroke, coronary heart disease and heart failure were found to be the main targets for cardiovascular prevention in published studies. Antihypertensive treatment has proven its efficacy in primary prevention of fatal or nonfatal stroke in hypertensive and high-risk patients >60 years of age, particularly through treatment of systolic hypertension. Systolic blood pressure reduction is equally important in the secondary prevention of stroke. Similarly, in nonvalvular atrial fibrillation, an adjusted dose of warfarin with a target International Normalized Ratio (INR) of between 2 to 3 prevents ischaemic stroke in elderly patients with an acceptable haemorrhagic risk but is still under prescribed. Antiplatelet agents are indicated in elderly patients with nonembolic strokes. Few large-scale studies have investigated the effect of HMG-CoA reductase inhibitors (statins) on stroke prevention in old individuals. To date, the largest trials suggest a beneficial effect for stroke prevention with use of statins in high-risk elderly subjects ≤82 years of age. Carotid endarterectomy is indicated in carotid artery stenosis >70% and outcomes are even better in elderly than in younger patients. However, medical treatment is still the first-line treatment in asymptomatic elderly patients with <70% stenosis. In ischaemic heart disease, different trials in elderly individuals have shown that use of statins, antithrombotic agents, β-adrenoceptor antagonists and ACE inhibitors plays an important role either in primary or in secondary cardiovascular prevention. Hormone replacement therapy has been used to treat climacteric symptoms and postmenopausal osteoporosis and was thought to confer a cardiovascular protection. However, controlled trials in elderly individuals changed this false belief when it was found that there was no benefit and even a harmful cardiovascular effect during the first year of treatment. Smoking cessation, regular physical activity and healthy diet are, as in younger individuals, appropriate and effective measures for preventing cardiovascular events in the elderly. Finally, antihypertensive treatment and influenza vaccination are useful for heart failure prevention in elderly individuals.

Conclusions

Cardiovascular prevention should be more widely implemented in the elderly, including individuals aged ≥75 years, and this might contribute to improved healthy status and quality of life in this growing population.
Literatur
1.
Zurück zum Zitat Stary HC. Evolution and progression of atherosclerosis in coronary arteries of children and young adults. Arteriosclerosis 1989; 9Suppl. 1: 119–32 Stary HC. Evolution and progression of atherosclerosis in coronary arteries of children and young adults. Arteriosclerosis 1989; 9Suppl. 1: 119–32
2.
Zurück zum Zitat National Cholesterol Education Program. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. Arch Intern Med 1991; 151: 1071–84CrossRef National Cholesterol Education Program. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. Arch Intern Med 1991; 151: 1071–84CrossRef
3.
Zurück zum Zitat National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Circulation 1994; 89: 1333–445CrossRef National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Circulation 1994; 89: 1333–445CrossRef
4.
Zurück zum Zitat Castelli WB, Garrison RJ, Wilson PNF, et al. The incidence of coronary artery disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986; 256: 2835–8PubMedCrossRef Castelli WB, Garrison RJ, Wilson PNF, et al. The incidence of coronary artery disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986; 256: 2835–8PubMedCrossRef
5.
Zurück zum Zitat Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial risk factor changes and mortality results. JAMA 1982; 248: 1465–76CrossRef Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial risk factor changes and mortality results. JAMA 1982; 248: 1465–76CrossRef
6.
Zurück zum Zitat Assmann G, Schulte H. The Prospective Cardiovascular Muenster (PROCAM) Study: prevalence of hypertension and/or diabetes mellitus and the relation to coronary heart disease. Am Heart J 1988; 116: 1713–24PubMedCrossRef Assmann G, Schulte H. The Prospective Cardiovascular Muenster (PROCAM) Study: prevalence of hypertension and/or diabetes mellitus and the relation to coronary heart disease. Am Heart J 1988; 116: 1713–24PubMedCrossRef
8.
Zurück zum Zitat Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126–46PubMedCrossRef Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126–46PubMedCrossRef
9.
Zurück zum Zitat Schwartz CJ, Mitchell JRA. Cellular infiltration of the human arterial adventitia associated with atheromatous plaques. Circulation 1962; 26: 73–8PubMedCrossRef Schwartz CJ, Mitchell JRA. Cellular infiltration of the human arterial adventitia associated with atheromatous plaques. Circulation 1962; 26: 73–8PubMedCrossRef
10.
Zurück zum Zitat Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994; 90: 1669–78PubMedCrossRef Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994; 90: 1669–78PubMedCrossRef
11.
Zurück zum Zitat World Health Organization. World health report 1999. Geneva: WHO, 1999 World Health Organization. World health report 1999. Geneva: WHO, 1999
13.
Zurück zum Zitat Warlow CP, Dennis MS, van Gijn G, et al. What caused this transient persisting ischaemic event? In: Warlow CP, Dennis HS, van Gijn J, et al., editors. Stroke: a practical guide to management. Oxford: Blackwell Science, 2001: 223–300 Warlow CP, Dennis MS, van Gijn G, et al. What caused this transient persisting ischaemic event? In: Warlow CP, Dennis HS, van Gijn J, et al., editors. Stroke: a practical guide to management. Oxford: Blackwell Science, 2001: 223–300
14.
Zurück zum Zitat Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effect of treatment on morbidity in hypertension: III. Influence of age, diastolic pressure and prior cardiovascular disease: future analysis of side effects. Circulation 1972; 45: 991–1004CrossRef Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effect of treatment on morbidity in hypertension: III. Influence of age, diastolic pressure and prior cardiovascular disease: future analysis of side effects. Circulation 1972; 45: 991–1004CrossRef
15.
Zurück zum Zitat Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of the Hypertension Detection and Follow-Up Program: II. Mortality by race, sex and age. JAMA 1979; 242: 2572–7CrossRef Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of the Hypertension Detection and Follow-Up Program: II. Mortality by race, sex and age. JAMA 1979; 242: 2572–7CrossRef
16.
Zurück zum Zitat Management Committee of the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Med J Aust 1981; 2: 398–402 Management Committee of the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Med J Aust 1981; 2: 398–402
17.
Zurück zum Zitat The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non disabling ischemic stroke. Stroke 1993; 24: 543–8CrossRef The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non disabling ischemic stroke. Stroke 1993; 24: 543–8CrossRef
18.
Zurück zum Zitat Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145–51PubMedCrossRef Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145–51PubMedCrossRef
19.
Zurück zum Zitat MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–12CrossRef MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–12CrossRef
20.
Zurück zum Zitat Eriksson S, Olofsson BO, Wester PO, for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovasc Dis 1995; 5: 21–5CrossRef Eriksson S, Olofsson BO, Wester PO, for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovasc Dis 1995; 5: 21–5CrossRef
21.
Zurück zum Zitat Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; I: 1349–54CrossRef Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; I: 1349–54CrossRef
22.
Zurück zum Zitat SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64CrossRef SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64CrossRef
23.
Zurück zum Zitat Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5PubMedCrossRef Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5PubMedCrossRef
24.
Zurück zum Zitat Bulpitt CJ, Beckett NS, Cooke J, et al. Hypertension in the Very Elderly Trial Working Group: results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21: 2409–17PubMedCrossRef Bulpitt CJ, Beckett NS, Cooke J, et al. Hypertension in the Very Elderly Trial Working Group: results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21: 2409–17PubMedCrossRef
25.
Zurück zum Zitat MacMahon S, Sharpe N, Gamble G, et al. Randomized placebo controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or occlusive arterial disease: prevention of atherosclerosis with ramipril. J Am Coll Cardiol 2000; 36: 438–43PubMedCrossRef MacMahon S, Sharpe N, Gamble G, et al. Randomized placebo controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or occlusive arterial disease: prevention of atherosclerosis with ramipril. J Am Coll Cardiol 2000; 36: 438–43PubMedCrossRef
26.
Zurück zum Zitat Teo KK, Burton JR, Buller CE, et al. Long term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102: 1748–54PubMedCrossRef Teo KK, Burton JR, Buller CE, et al. Long term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102: 1748–54PubMedCrossRef
27.
Zurück zum Zitat PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033–41CrossRef PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033–41CrossRef
28.
Zurück zum Zitat Heart Outcomes Prevention Evaluation Study Investigators (HOPE). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53CrossRef Heart Outcomes Prevention Evaluation Study Investigators (HOPE). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53CrossRef
29.
Zurück zum Zitat Thijs L, Staessen JA, Beleva S, et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe: follow-up study (Syst-Eur2). Curr Control Trials Cardiovasc Med 2001; 2: 298–306PubMedCrossRef Thijs L, Staessen JA, Beleva S, et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe: follow-up study (Syst-Eur2). Curr Control Trials Cardiovasc Med 2001; 2: 298–306PubMedCrossRef
30.
Zurück zum Zitat MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease: prolonged difference in blood pressure: prospective observational study corrected for the regression dilution bias. Lancet 1990; 335: 765–74PubMedCrossRef MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease: prolonged difference in blood pressure: prospective observational study corrected for the regression dilution bias. Lancet 1990; 335: 765–74PubMedCrossRef
31.
Zurück zum Zitat Mulrow CD, Cornell JA, Herrera CR, et al. Hypertension in the elderly: implication and generalizability of randomized trials. JAMA 1994; 272: 1932–8PubMedCrossRef Mulrow CD, Cornell JA, Herrera CR, et al. Hypertension in the elderly: implication and generalizability of randomized trials. JAMA 1994; 272: 1932–8PubMedCrossRef
32.
Zurück zum Zitat Staessen JA, Gazowski J, Wang JG, et al. Risk of untreated and treated isolated systolic hypertension in the elderly: meta analysis of outcome trials. Lancet 2000; 355: 865–72PubMedCrossRef Staessen JA, Gazowski J, Wang JG, et al. Risk of untreated and treated isolated systolic hypertension in the elderly: meta analysis of outcome trials. Lancet 2000; 355: 865–72PubMedCrossRef
33.
Zurück zum Zitat Lawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35: 1024–33PubMedCrossRef Lawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35: 1024–33PubMedCrossRef
34.
Zurück zum Zitat Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999; 353: 793–6PubMedCrossRef Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999; 353: 793–6PubMedCrossRef
35.
Zurück zum Zitat Bosch J, Yusuf S, Pogue J, et al. Heart Outcomes Prevention Evaluation: use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 699–702PubMedCrossRef Bosch J, Yusuf S, Pogue J, et al. Heart Outcomes Prevention Evaluation: use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 699–702PubMedCrossRef
36.
Zurück zum Zitat Kannel WB, Abbot RD, Savage DD, et al. Epidemiological features of atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018–22PubMedCrossRef Kannel WB, Abbot RD, Savage DD, et al. Epidemiological features of atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018–22PubMedCrossRef
37.
Zurück zum Zitat Wolf PA, Dawber TR, Thomas Jr HE, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: 973–7PubMedCrossRef Wolf PA, Dawber TR, Thomas Jr HE, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: 973–7PubMedCrossRef
38.
39.
Zurück zum Zitat Atrial Fibrillation Investigators. Risk factor for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomised controlled trials. Arch Intern Med 1994; 154: 1449–57CrossRef Atrial Fibrillation Investigators. Risk factor for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomised controlled trials. Arch Intern Med 1994; 154: 1449–57CrossRef
40.
Zurück zum Zitat Hart R, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patient with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492–501PubMed Hart R, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patient with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492–501PubMed
41.
Zurück zum Zitat Connolly SJ. The Atrial Fibrillation Investigators: stroke prevention in atrial fibrillation II study. Lancet 1994; 343: 1508–9CrossRef Connolly SJ. The Atrial Fibrillation Investigators: stroke prevention in atrial fibrillation II study. Lancet 1994; 343: 1508–9CrossRef
42.
Zurück zum Zitat Stroke Prevention in Atrial Fibrillation Investigators. Adjusted dose warfarin versus low intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633–8CrossRef Stroke Prevention in Atrial Fibrillation Investigators. Adjusted dose warfarin versus low intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633–8CrossRef
43.
Zurück zum Zitat The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with non rheumatic atrial fibrillation and recent cerebral ischemia: the European Atrial Fibrillation Trial Study Group. N Engl J Med 1995; 333: 5–10CrossRef The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with non rheumatic atrial fibrillation and recent cerebral ischemia: the European Atrial Fibrillation Trial Study Group. N Engl J Med 1995; 333: 5–10CrossRef
44.
Zurück zum Zitat Levine MN, Chair MS, Raskob G, et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119: 108S–21SPubMedCrossRef Levine MN, Chair MS, Raskob G, et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119: 108S–21SPubMedCrossRef
45.
Zurück zum Zitat Van der Meer FJ, Rosendall FR, Vanderbroocke JP, et al. Bleeding complications in oral anticoagulant therapy, an analysis of risk factors. Arch Intern Med 1993; 153: 1557–62PubMedCrossRef Van der Meer FJ, Rosendall FR, Vanderbroocke JP, et al. Bleeding complications in oral anticoagulant therapy, an analysis of risk factors. Arch Intern Med 1993; 153: 1557–62PubMedCrossRef
46.
Zurück zum Zitat Palareti G, Hirsh J, Legnani C, et al. Oral anticoagulant treatment in elderly: a nested prospective, case control study. Arch Intern Med 2000; 160: 470–8PubMedCrossRef Palareti G, Hirsh J, Legnani C, et al. Oral anticoagulant treatment in elderly: a nested prospective, case control study. Arch Intern Med 2000; 160: 470–8PubMedCrossRef
47.
Zurück zum Zitat Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin: the National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 124: 970–9PubMed Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin: the National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 124: 970–9PubMed
48.
Zurück zum Zitat Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997; 28: 2382–9PubMedCrossRef Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997; 28: 2382–9PubMedCrossRef
49.
Zurück zum Zitat White RH, McBurnie MA, Manolio T, et al. Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. Am J Med 1999; 106: 165–71PubMedCrossRef White RH, McBurnie MA, Manolio T, et al. Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. Am J Med 1999; 106: 165–71PubMedCrossRef
50.
Zurück zum Zitat Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685–92PubMedCrossRef Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685–92PubMedCrossRef
51.
Zurück zum Zitat Vasishta S, Toor F, Johansen A, et al. Stroke prevention in atrial fibrillation: physicians’ attitudes to anticoagulation in older people. Arch Gerontol Geriatr 2001; 33: 219–26PubMedCrossRef Vasishta S, Toor F, Johansen A, et al. Stroke prevention in atrial fibrillation: physicians’ attitudes to anticoagulation in older people. Arch Gerontol Geriatr 2001; 33: 219–26PubMedCrossRef
52.
Zurück zum Zitat Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk of falls. Arch Intern Med 1999; 159: 677–85PubMedCrossRef Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk of falls. Arch Intern Med 1999; 159: 677–85PubMedCrossRef
53.
Zurück zum Zitat Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with non valvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690–8PubMedCrossRef Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with non valvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690–8PubMedCrossRef
54.
Zurück zum Zitat Zhang X, Patel A, Horibe H, et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003; 32: 563–72PubMedCrossRef Zhang X, Patel A, Horibe H, et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003; 32: 563–72PubMedCrossRef
55.
Zurück zum Zitat Rodriguez BL, D’Agostino R, Abbott RD, et al. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: a comparison of incidence and risk factor effects. Stroke 2002; 33: 230–6PubMedCrossRef Rodriguez BL, D’Agostino R, Abbott RD, et al. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: a comparison of incidence and risk factor effects. Stroke 2002; 33: 230–6PubMedCrossRef
56.
Zurück zum Zitat Scandinavian Simvastatin Survival study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9 Scandinavian Simvastatin Survival study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9
57.
Zurück zum Zitat Plehn JF, Davis BR, Sacks FM, et al., for the CARE Investigators. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) Study. Circulation 1999; 99: 216–23PubMedCrossRef Plehn JF, Davis BR, Sacks FM, et al., for the CARE Investigators. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) Study. Circulation 1999; 99: 216–23PubMedCrossRef
58.
Zurück zum Zitat West Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440–5CrossRef West Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440–5CrossRef
59.
Zurück zum Zitat Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–30PubMedCrossRef Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–30PubMedCrossRef
60.
Zurück zum Zitat Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high risk conditions. Lancet 2004; 363: 757–67CrossRef Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high risk conditions. Lancet 2004; 363: 757–67CrossRef
61.
Zurück zum Zitat Pohjasvaara T, Erkinjuntii T, Vataja R, et al. Comparison of stroke features and disability in daily life in patients with ischemic stroke aged 55 to 70 and 71 to 85 years. Stroke 1997; 28: 729–35PubMedCrossRef Pohjasvaara T, Erkinjuntii T, Vataja R, et al. Comparison of stroke features and disability in daily life in patients with ischemic stroke aged 55 to 70 and 71 to 85 years. Stroke 1997; 28: 729–35PubMedCrossRef
62.
Zurück zum Zitat European Carotid Surgery Trialists’ Collaborative group. MRC European Carotid Surgery Trial: interim result for symptomatic patients with severe (70–99) or mild (0–29) carotid stenosis. Lancet 1991; 337: 1235–43CrossRef European Carotid Surgery Trialists’ Collaborative group. MRC European Carotid Surgery Trial: interim result for symptomatic patients with severe (70–99) or mild (0–29) carotid stenosis. Lancet 1991; 337: 1235–43CrossRef
63.
Zurück zum Zitat Alamowitch S, Eliasziw M, Algra A, et al. Risk, causes, and prevention of ischemic stroke in elderly patients with symptomatic internal carotid artery stenosis. Lancet 2001; 357: 1154–60PubMedCrossRef Alamowitch S, Eliasziw M, Algra A, et al. Risk, causes, and prevention of ischemic stroke in elderly patients with symptomatic internal carotid artery stenosis. Lancet 2001; 357: 1154–60PubMedCrossRef
64.
Zurück zum Zitat Barnett H. The appropriate use of carotid endarterectomy. CMAJ 2002; 166: 1169–79PubMed Barnett H. The appropriate use of carotid endarterectomy. CMAJ 2002; 166: 1169–79PubMed
65.
Zurück zum Zitat Asymptomatic Carotid Atherosclerosis Study Group. Study design for randomised prospective trial of carotid endarterectomy for asymptomatic atherosclerosis. Stroke 1989; 20: 844–9CrossRef Asymptomatic Carotid Atherosclerosis Study Group. Study design for randomised prospective trial of carotid endarterectomy for asymptomatic atherosclerosis. Stroke 1989; 20: 844–9CrossRef
66.
Zurück zum Zitat Swedish Aspirin Low-Dose Trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. The SALT Collaborative Group. Lancet 1991; 338: 1345–9 Swedish Aspirin Low-Dose Trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. The SALT Collaborative Group. Lancet 1991; 338: 1345–9
67.
Zurück zum Zitat Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; I: 1215–20CrossRef Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; I: 1215–20CrossRef
68.
Zurück zum Zitat Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13PubMedCrossRef Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13PubMedCrossRef
69.
Zurück zum Zitat Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003; 289: 2947–57PubMedCrossRef Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003; 289: 2947–57PubMedCrossRef
70.
Zurück zum Zitat CAPRIE Steering Committee. A randomized, blinded trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996; 348: 1329–39CrossRef CAPRIE Steering Committee. A randomized, blinded trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996; 348: 1329–39CrossRef
71.
Zurück zum Zitat Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86CrossRef Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86CrossRef
72.
Zurück zum Zitat Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106CrossRef Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106CrossRef
73.
Zurück zum Zitat Griffin G. Antiplatelet therapy and anticoagulation in patients with hypertension. Am Fam Physician 2005; 71: 897–9PubMed Griffin G. Antiplatelet therapy and anticoagulation in patients with hypertension. Am Fam Physician 2005; 71: 897–9PubMed
74.
Zurück zum Zitat Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–62PubMedCrossRef Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–62PubMedCrossRef
75.
Zurück zum Zitat Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444–51PubMedCrossRef Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444–51PubMedCrossRef
76.
Zurück zum Zitat Algra A, De Schryver ELLM, van Gijn J, et al. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2001; (4): CD001342 Algra A, De Schryver ELLM, van Gijn J, et al. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2001; (4): CD001342
77.
Zurück zum Zitat Shepherd J, Cobbe SM, Ford I, et al. The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7PubMedCrossRef Shepherd J, Cobbe SM, Ford I, et al. The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7PubMedCrossRef
78.
Zurück zum Zitat Downs JR, Clearfield M, Weis S, et al. The AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–22PubMedCrossRef Downs JR, Clearfield M, Weis S, et al. The AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–22PubMedCrossRef
79.
Zurück zum Zitat The MASS Investigators. Effect of simvastatin on coronary atheroma, the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633–8CrossRef The MASS Investigators. Effect of simvastatin on coronary atheroma, the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633–8CrossRef
80.
81.
Zurück zum Zitat Colli S, Eligini S, Lalli M, et al. Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 265–72PubMedCrossRef Colli S, Eligini S, Lalli M, et al. Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 265–72PubMedCrossRef
82.
Zurück zum Zitat Mayer L, Eller T, Brauer P, et al. Effect of long term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992; 64: 196–201PubMedCrossRef Mayer L, Eller T, Brauer P, et al. Effect of long term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992; 64: 196–201PubMedCrossRef
83.
Zurück zum Zitat Cairns JA, Theroux P, Lewis Jr HD, et al. Anti-thrombotic agents in coronary artery disease. Chest 2001; 119: S228–52CrossRef Cairns JA, Theroux P, Lewis Jr HD, et al. Anti-thrombotic agents in coronary artery disease. Chest 2001; 119: S228–52CrossRef
84.
Zurück zum Zitat Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969–74PubMedCrossRef Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969–74PubMedCrossRef
85.
Zurück zum Zitat Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003; 362: 789–97PubMedCrossRef Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003; 362: 789–97PubMedCrossRef
86.
Zurück zum Zitat The Norwegian Multicenter Study Group. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801–7CrossRef The Norwegian Multicenter Study Group. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801–7CrossRef
87.
Zurück zum Zitat Shilpak MG, Browner WS, Noguchi H, et al. Comparison of the effects of angiotensin converting enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. Am J Med 2001; 110: 425–33CrossRef Shilpak MG, Browner WS, Noguchi H, et al. Comparison of the effects of angiotensin converting enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. Am J Med 2001; 110: 425–33CrossRef
88.
Zurück zum Zitat Rochon PA, Tu JV, Anderson GM, et al. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. Lancet 2000; 356: 639–44PubMedCrossRef Rochon PA, Tu JV, Anderson GM, et al. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. Lancet 2000; 356: 639–44PubMedCrossRef
89.
Zurück zum Zitat Wei L, Flynn R, Murray GD, et al. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment? Pharmacoepidemiol Drug Saf 2004; 13: 761–6PubMedCrossRef Wei L, Flynn R, Murray GD, et al. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment? Pharmacoepidemiol Drug Saf 2004; 13: 761–6PubMedCrossRef
90.
Zurück zum Zitat Everly MJ, Heaton PC, Cluxton Jr RJ. Beta-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother 2004; 38: 286–93PubMed Everly MJ, Heaton PC, Cluxton Jr RJ. Beta-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother 2004; 38: 286–93PubMed
91.
Zurück zum Zitat Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fraction. Lancet 1992; 340: 1173–8PubMedCrossRef Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fraction. Lancet 1992; 340: 1173–8PubMedCrossRef
92.
Zurück zum Zitat The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with evidence of heart failure. Lancet 1993; 342: 821–8 The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with evidence of heart failure. Lancet 1993; 342: 821–8
93.
Zurück zum Zitat Stampfer MJ, Colditz GA, Willet WC, et al. Post menopausal estrogen therapy and cardiovascular disease: ten-year follow up from the Nurses’ Health Study. N Engl J Med 1991; 325: 756–62PubMedCrossRef Stampfer MJ, Colditz GA, Willet WC, et al. Post menopausal estrogen therapy and cardiovascular disease: ten-year follow up from the Nurses’ Health Study. N Engl J Med 1991; 325: 756–62PubMedCrossRef
94.
Zurück zum Zitat Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of ischemic heart disease in post menopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–13PubMedCrossRef Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of ischemic heart disease in post menopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–13PubMedCrossRef
95.
Zurück zum Zitat Cherry N, Gilmour K, Hannoford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002; 360: 2001–8PubMedCrossRef Cherry N, Gilmour K, Hannoford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002; 360: 2001–8PubMedCrossRef
96.
Zurück zum Zitat Stevenson JC, Oladipo A, Manassiev N, et al. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol 2004; 124: 802–8PubMedCrossRef Stevenson JC, Oladipo A, Manassiev N, et al. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol 2004; 124: 802–8PubMedCrossRef
97.
Zurück zum Zitat Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1116–21PubMedCrossRef Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1116–21PubMedCrossRef
98.
Zurück zum Zitat Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–44PubMedCrossRef Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–44PubMedCrossRef
99.
Zurück zum Zitat Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997; 278: 212–6PubMedCrossRef Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997; 278: 212–6PubMedCrossRef
100.
Zurück zum Zitat ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97CrossRef ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97CrossRef
101.
Zurück zum Zitat Arnold JM, Yusuf S, Young J, et al. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003; 107: 1284–90PubMedCrossRef Arnold JM, Yusuf S, Young J, et al. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003; 107: 1284–90PubMedCrossRef
102.
Zurück zum Zitat Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348: 1322–32PubMedCrossRef Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348: 1322–32PubMedCrossRef
103.
Zurück zum Zitat LaCroix AZ, Lang J, Scherr P, et al. Smoking and mortality among older men and women in three communities. N Engl J Med 1991; 324: 1619–25PubMedCrossRef LaCroix AZ, Lang J, Scherr P, et al. Smoking and mortality among older men and women in three communities. N Engl J Med 1991; 324: 1619–25PubMedCrossRef
104.
Zurück zum Zitat Ho SC, Zhan SY, Tang JL, et al. Smoking and mortality in an older Chinese cohort. J Am Geriatr Soc 1999; 47: 1445–50PubMed Ho SC, Zhan SY, Tang JL, et al. Smoking and mortality in an older Chinese cohort. J Am Geriatr Soc 1999; 47: 1445–50PubMed
105.
Zurück zum Zitat Tessier JF, Nejjari C, Letenneur L, et al. Smoking and eight-year mortality in an elderly cohort. Int J Tuberc Lung Dis 2000; 4: 698–704PubMed Tessier JF, Nejjari C, Letenneur L, et al. Smoking and eight-year mortality in an elderly cohort. Int J Tuberc Lung Dis 2000; 4: 698–704PubMed
106.
Zurück zum Zitat Dale LC, Olsen DA, Patten CA, et al. Predictors of smoking cessation among elderly smokers treated for nicotine dependence. Tob Control 1997; 6: 181–7PubMedCrossRef Dale LC, Olsen DA, Patten CA, et al. Predictors of smoking cessation among elderly smokers treated for nicotine dependence. Tob Control 1997; 6: 181–7PubMedCrossRef
107.
Zurück zum Zitat Orleans CT, Resch N, Noll E, et al. Use of transdermal nicotine in a state-level prescription plan for the elderly: a first look at ‘real-world’ patch users. JAMA 1994; 271: 601–7PubMedCrossRef Orleans CT, Resch N, Noll E, et al. Use of transdermal nicotine in a state-level prescription plan for the elderly: a first look at ‘real-world’ patch users. JAMA 1994; 271: 601–7PubMedCrossRef
108.
Zurück zum Zitat Daughton D, Susman J, Sitorius M, et al. Transdermal nicotine therapy and primary care. Importance of counselling, demographic, and participant selection factors on 1-year quit rates: the Nebraska Primary Practice Smoking Cessation Trial Group. Arch Fam Med 1998; 7: 425–30PubMedCrossRef Daughton D, Susman J, Sitorius M, et al. Transdermal nicotine therapy and primary care. Importance of counselling, demographic, and participant selection factors on 1-year quit rates: the Nebraska Primary Practice Smoking Cessation Trial Group. Arch Fam Med 1998; 7: 425–30PubMedCrossRef
109.
Zurück zum Zitat Powell KE, Thompson PD, Caspersen CJ, et al. Physical activity and the incidence of coronary artery disease. Annu Rev Public Health 1987; 8: 253–87PubMedCrossRef Powell KE, Thompson PD, Caspersen CJ, et al. Physical activity and the incidence of coronary artery disease. Annu Rev Public Health 1987; 8: 253–87PubMedCrossRef
110.
Zurück zum Zitat Paffenbarger RS, Hyde RT, Wing AL, et al. The association of changes in physical activity levels and other lifestyle characteristics with mortality among men. N Engl J Med 1993; 328: 538–45PubMedCrossRef Paffenbarger RS, Hyde RT, Wing AL, et al. The association of changes in physical activity levels and other lifestyle characteristics with mortality among men. N Engl J Med 1993; 328: 538–45PubMedCrossRef
111.
Zurück zum Zitat Rosengren A, Wilhelmsen L. Physical activity protects against coronary death and deaths from all causes in middle-aged men: evidence from a 20-year follow-up of the primary prevention study in Goteborg. Ann Epidemiol 1997; 7: 69–75PubMedCrossRef Rosengren A, Wilhelmsen L. Physical activity protects against coronary death and deaths from all causes in middle-aged men: evidence from a 20-year follow-up of the primary prevention study in Goteborg. Ann Epidemiol 1997; 7: 69–75PubMedCrossRef
112.
Zurück zum Zitat Eaton CB, Medalie JH, Flocke SA, et al. Self-reported physical activity predicts long-term coronary heart disease and all-cause mortalities: twenty-one-year follow-up of the Israeli Ischemic Heart Disease Study. Arch Fam Med 1995; 4: 323–9PubMedCrossRef Eaton CB, Medalie JH, Flocke SA, et al. Self-reported physical activity predicts long-term coronary heart disease and all-cause mortalities: twenty-one-year follow-up of the Israeli Ischemic Heart Disease Study. Arch Fam Med 1995; 4: 323–9PubMedCrossRef
113.
Zurück zum Zitat Wannamethee SG, Gerald Shaper A, Walker M. Changes in physical activity, mortality, and incidence of coronary heart disease in older men. Lancet 1998; 351: 1603–8PubMedCrossRef Wannamethee SG, Gerald Shaper A, Walker M. Changes in physical activity, mortality, and incidence of coronary heart disease in older men. Lancet 1998; 351: 1603–8PubMedCrossRef
114.
Zurück zum Zitat Gregg EW, Cauley JA, Stone K, et al. Relationship of changes in physical activity and mortality among older women. JAMA 2003; 289: 2379–86PubMedCrossRef Gregg EW, Cauley JA, Stone K, et al. Relationship of changes in physical activity and mortality among older women. JAMA 2003; 289: 2379–86PubMedCrossRef
115.
Zurück zum Zitat Schnohr P, Scharling H, Jensen JS. Changes in leisure-time physical activity and risk of death: an observational study of 7000 men and women. Am J Epidemiol 2003; 158: 639–44PubMedCrossRef Schnohr P, Scharling H, Jensen JS. Changes in leisure-time physical activity and risk of death: an observational study of 7000 men and women. Am J Epidemiol 2003; 158: 639–44PubMedCrossRef
116.
Zurück zum Zitat Lavie CJ, Milani RV. Benefits of cardiac rehabilitation and exercise training programs in elderly coronary patients. Am J Geriatr Cardiol 2001; 10: 323–7PubMedCrossRef Lavie CJ, Milani RV. Benefits of cardiac rehabilitation and exercise training programs in elderly coronary patients. Am J Geriatr Cardiol 2001; 10: 323–7PubMedCrossRef
117.
Zurück zum Zitat Hung C, Daub B, Black B, et al. Exercise training improves overall physical fitness and quality of life in older women with coronary artery disease. Chest 2004; 126: 1026–31PubMedCrossRef Hung C, Daub B, Black B, et al. Exercise training improves overall physical fitness and quality of life in older women with coronary artery disease. Chest 2004; 126: 1026–31PubMedCrossRef
118.
Zurück zum Zitat Lavie CJ, Milani RV, Littman AB. Benefit of cardiac rehabilitation and exercise training in secondary coronary prevention in the elderly. J Am Coll Cardiol 1993; 22: 678–83PubMedCrossRef Lavie CJ, Milani RV, Littman AB. Benefit of cardiac rehabilitation and exercise training in secondary coronary prevention in the elderly. J Am Coll Cardiol 1993; 22: 678–83PubMedCrossRef
119.
Zurück zum Zitat Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343: 16–22PubMedCrossRef Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343: 16–22PubMedCrossRef
120.
Zurück zum Zitat Mozaffarian D, Longstreth Jr WT, Lemaitre RN, et al. Fish consumption and stroke risk in elderly individuals: the Cardiovascular Health Study. Arch Intern Med 2005; 165: 200–6PubMedCrossRef Mozaffarian D, Longstreth Jr WT, Lemaitre RN, et al. Fish consumption and stroke risk in elderly individuals: the Cardiovascular Health Study. Arch Intern Med 2005; 165: 200–6PubMedCrossRef
121.
Zurück zum Zitat Huijbregts P, Feskens E, Räsänen L, et al. Dietary pattern and 20-year mortality in elderly men in Finland, Italy, and the Netherlands: longitudinal cohort study. BMJ 1997; 315: 13–7PubMedCrossRef Huijbregts P, Feskens E, Räsänen L, et al. Dietary pattern and 20-year mortality in elderly men in Finland, Italy, and the Netherlands: longitudinal cohort study. BMJ 1997; 315: 13–7PubMedCrossRef
122.
Zurück zum Zitat Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004; 292: 1433–9PubMedCrossRef Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004; 292: 1433–9PubMedCrossRef
123.
Zurück zum Zitat Janszky I, Mukamal KJ, Orth-Gomer K, et al. Alcohol consumption and coronary atherosclerosis progression: the Stockholm Female Coronary Risk Angiographic Study. Atherosclerosis 2004; 176: 311–9PubMedCrossRef Janszky I, Mukamal KJ, Orth-Gomer K, et al. Alcohol consumption and coronary atherosclerosis progression: the Stockholm Female Coronary Risk Angiographic Study. Atherosclerosis 2004; 176: 311–9PubMedCrossRef
124.
Zurück zum Zitat Hooper L, Bartlett C, Davey SG, et al. Advice to reduce dietary salt for prevention of cardiovascular disease. Cochrane Database Syst Rev 2004; (1): CD003656 Hooper L, Bartlett C, Davey SG, et al. Advice to reduce dietary salt for prevention of cardiovascular disease. Cochrane Database Syst Rev 2004; (1): CD003656
125.
Zurück zum Zitat Hart RG. Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young. Heart 1999; 82: 539–40PubMed Hart RG. Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young. Heart 1999; 82: 539–40PubMed
126.
Zurück zum Zitat Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999; 14: 711–7PubMedCrossRef Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999; 14: 711–7PubMedCrossRef
127.
Zurück zum Zitat Hulley SB, Grady D, Browner WS. Statins: underused by those who would benefit: but caution is needed for young people at low risk of cardiovascular disease. BMJ 2000; 321: 971–2PubMedCrossRef Hulley SB, Grady D, Browner WS. Statins: underused by those who would benefit: but caution is needed for young people at low risk of cardiovascular disease. BMJ 2000; 321: 971–2PubMedCrossRef
128.
Zurück zum Zitat Everly MJ, Heaton PC, Cluxton Jr RJ. Beta-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother 2004; 38: 286–93PubMed Everly MJ, Heaton PC, Cluxton Jr RJ. Beta-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother 2004; 38: 286–93PubMed
129.
Zurück zum Zitat Foody JM, Ferdinand FD, Galusha D, et al. Patterns of secondary prevention in older patients undergoing coronary artery bypass grafting during hospitalization for acute myocardial infarction. Circulation 2003; 108Suppl. 1: II24–8PubMed Foody JM, Ferdinand FD, Galusha D, et al. Patterns of secondary prevention in older patients undergoing coronary artery bypass grafting during hospitalization for acute myocardial infarction. Circulation 2003; 108Suppl. 1: II24–8PubMed
Metadaten
Titel
Prevention of Cardiovascular Events in Elderly People
verfasst von
Wafik Farah Andrawes
Caroline Bussy
Professor Joël Belmin
Publikationsdatum
01.10.2005
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 10/2005
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200522100-00005

Weitere Artikel der Ausgabe 10/2005

Drugs & Aging 10/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.